4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at three healthcare conferences in March 2026.
Presentations are scheduled at TD Cowen on March 3, 2026 at 10:30 a.m. ET, Leerink on March 10, 2026 at 4:20 p.m. ET, and Barclays on March 12, 2026 at 9:00 a.m. ET. Webcasts will be archived for up to one year on the company Investors site.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on February 10, 2026 its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees under the Company’s 2025 Employment Inducement Award Plan.
The awards were made pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to induce new employees to join the company.
4D Molecular Therapeutics (Nasdaq: FDMT) announced completion of enrollment for 4FRONT-1, the first Phase 3 registrational trial of 4D-150 in wet age-related macular degeneration (wet AMD), achieved in approximately 11 months and with over-enrollment expected to exceed 500 randomized patients.
Topline primary endpoint data for 4FRONT-1 is expected in H1 2027; global activation for 4FRONT-2 continues with enrollment on track for completion in H2 2026 and topline data expected in H2 2027.
4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 under Nasdaq Rule 5635(c)(4) to permit equity grants that induce new hires to join the company.
4D Molecular Therapeutics (Nasdaq: FDMT) provided a 2026 corporate update highlighting accelerated late-stage retinal programs, leadership changes and financial runway. Key clinical milestones include an increased 4FRONT Phase 3 target enrollment to 480 patients per trial (≈90% power), 381 patients randomized or approved to randomize in 4FRONT-1 as of Jan 6, 2026, with North America enrollment on track to complete in Q1 2026 and topline data expected in H1 2027. Ex-U.S. enrollment for 4FRONT-2 aims to finish in H2 2026 with topline in H2 2027. PRISM 2-year Phase 2b data expected mid-2026; SPECTRA 2-year data and DME Phase 3 plans expected in H2 2026. Leadership updates include board addition Glenn Sblendorio and executive promotions, and cash of $514 million is expected to fund operations into H2 2028.
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim Phase 1 AEROW data for 4D-710 in cystic fibrosis lung disease (data cutoff Dec 1, 2025).
Key points: 16 participants enrolled across four dose cohorts (2E15, 1E15, 5E14, 2.5E14 vg) with follow-up from 4 months to 3.5 years. The company selected 2.5E14 vg as the Phase 2 dose after dose-dependent, durable CFTR transgene expression at or above physiologically relevant levels and clinically meaningful improvements in ppFEV1, LCI2.5 and CFQ-R through 1 year. Safety: no new pulmonary or other safety events in higher-dose cohorts; lower-dose AEs were generally mild and transient. Next milestones: complete Phase 2 dose-expansion (target n=6) in H1 2026; program update in H2 2026.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on December 9, 2025 its compensation committee granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.
The inducement plan was approved by the board in February 2025 and is being used pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to attract new hires.
4D Molecular Therapeutics (NASDAQ: FDMT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan 14, 2026. The presentation is scheduled for 7:30 a.m. PT and will be available via webcast.
Members of 4DMT management will be available for one-on-one meetings. An archived copy of the webcast will be available for up to one year in the company’s Investors events section at the investor website.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference and will be available for one-on-one meetings.
The presentation is scheduled for Wednesday, Dec 3, 2025 at 2:35 p.m. ET. A live webcast will be available and archived copies will remain on the company's Investors website for up to one year.
4D Molecular Therapeutics (Nasdaq: FDMT) appointed Kristian Humer as Chief Financial Officer effective Nov 17, 2025. He will lead financial planning, capital allocation, corporate development and strategic initiatives as the company advances multiple Phase 3 programs and prepares for commercial readiness.
Humer brings more than 20 years of finance experience, including senior roles at Citi healthcare investment banking (2010–2021) and prior CFO positions at Foghorn Therapeutics and Viridian Therapeutics. He holds an MBA from Duke Fuqua and a BA (Hons) in accounting and economics from the University of Reading.